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Resorbable polymer of hydroxybutyric acid labeled with 14C was used to prepare microparticles 
(diameter smaller than 3.8 µm ) that were then injected to laboratory animals (Wistar rats) via the tail 
vein, without causing any adverse effects on growth and development of the animals or altering the 
macroscopic and microscopic structure of the tissues of internal organs. Examination of the distribution 
of microparticles among the internal organs and the dynamics of accumulation of carbon-containing 
polymer degradation products in internal organs showed that the main targets for microparticles were 
tissues of the liver, kidneys, and spleen. The most rapid degradation of the polymer of microparticles 
occurred in the spleen and liver. The presence of high molecular weight polymer registered in internal 
organs suggested that the microparticles remained undecomposed and that the PHB microparticles 
could function in vivo for extended periods of time (up to 12 weeks). 
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Introduction
Designing of controlled-release drug 
delivery systems is a promising and rapidly 
developing line of modern pharmacology (Amass 
et al., 1998). Drug delivery systems in the form of 
biodegradable microspheres and microcapsules 
can be injected subcutaneously, intramuscularly 
and into the bloodstream (Freiberg et al., 2004). 
Drug delivery systems intended for intravenous 
injection must be not only biocompatible but 
also hemocompatible, i.e. the materials used 
to construct them must not induce thromboses, 
thromboembolisms, antigenic response or 
destruction of blood constituents and plasma 
proteins; they must also retain their mechanical-
physical properties (Yen et al., 2003; Kim et al., 
2004).
Bioresorbable polyesters of microbiological 
origin – polyhydroxyalkanoates (PHAs) – are 
considered to be promising materials to be used as 
scaffold carriers for drug delivery (Amara et al., 
2008). Polyhydroxybutyrate was used as a basis 
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for production of polymer scaffold constructions 
in the form of films, tablets, and microparticles 
(Sevastianov et al., 2003; Shishatskaya et al., 
2006); it was proved that PHB microparticles 
were highly biocompatible and could be injected 
intramuscularly (Shishatskaya et al., 2008a); 
experiments with PHB scaffolds loaded with 
rubomycin hydrochloride showed their suitability 
as carriers of anticancer drugs (Shishatskaya et 
al., 2008b). It should be mentioned that today 
the number of PHA studies devoted to the 
development of controlled-release systems is 
considerably less than the number of similar 
studies based on biodegradable polylactides and 
polyglycolides. 
Today antibiotics, hormonal agents and 
anticancer drugs in the form of microparticles 
can be deposited into PHA matrices (Abe and 
Doi 1992; Kassab et al., 1997; Lionzo et al., 
2007; Wang et al., 2007; Bazzo et al., 2008). PHA 
biocompatibility was proven in vitro using cells 
of different origins (Choi et al., 2005) and in in 
vivo experiments (Gogolewski et al., 1993; Qu et 
al., 2006). 
However, despite the existing data about 
using PHAs for the microencapsulation of drugs, 
the problem of biocompatibility of polymer 
particles as carriers for drugs to be administered 
intravenously is not covered in the available 
literature. One of the earliest investigations 
devoted to the possible intravenous administration 
of PHA microparticles was performed by 
Bissery et al., 1984. Using the method of solvent 
evaporation from the 14C-labeled PHB solution, 
microspheres were obtained with the diameter of 
1-12 µm and injected intravenously to mice; after 
the injection the microspheres were localized 
mainly in lungs. However, introduction of these 
microspheres loaded with the anticancer agent, 
lomustine, to Levis’ mice infected with carcinoma 
had minimal effect. In addition, the location of 
14C-labeled polyhydroxybutyrate granules was 
investigated with the intravenous injection (Saito 
et al., 1991).
E.T. Baran and co-authors (2002) studied the 
toxicity and half life of encapsulated L-asparaginase 
(ASNase) in poly (3-hydroxybutyrate-co-3-
hydroxyvalerate) PHBV nanocapsules in mice. 
The PHBV nanocapsules with heparin conjugated 
on their surface had a longer presence in the 
circulation than unmodified PHBV nanocapsules. 
No adverse effects were observed upon injection 
of encapsulated ASNase-PHBV nanocapsules to 
mice i.v. through the tail vein.
The purpose of this study was to examine the 
distribution of PHB microparticles in the internal 
organs of laboratory animals; biocompatibility 
of PHB microparticles and their life-time in the 
organism after intravenous injection; distribution 
dynamics of microparticles and degradation 
products in the internal organs of laboratory 
animals.
Materials and methods
1. Preparation of 14C-labeled PHB polymer
The tested material was the 
polyhydroxybutyrate (PHB) samples synthesized 
by the bacterium Ralstonia eutropha B5786 (Mw 
340 000 Da, crystallinity 70-78 %). The strain is 
registered in the Russian Collection of Industrial 
Microorganisms. The 14C-labeled polymer was 
prepared by adding 1,2-14C-acetate (6×104 cpm/
ml; cpm- counts per minute) as substrate to 
the bacterial culture in the polymer synthesis 
phase. PHB is extractable from the bacterial 
biomass due to its ability to dissolve in organic 
solvents and to be then precipitated by alcohols. 
PHB was extracted from the bacterial biomass 
with chloroform and precipitated with ethanol. 
The procedure of re-dissolution and further 
precipitation of polymer was repeated several 
times to prepare specimens that would not contain 
organic impurities of protein, carbohydrate or 
lipid nature. We have previously shown that this 
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procedure can be used to prepare high-purity PHB 
specimens, which would not contain any organic 
impurities – components of bacterial biomass – 
and would exhibit excellent biocompatibility 
characteristics, allowing them to contact blood. 
The trademark of the material is Bioplastotan 
(Trademark «BIOPLASTOTANTM»). The 
radioactivity of the prepared PHB was 1.4×104 
cpm per 1 mg of the polymer. The radioactivity of 
the samples was measured using the TRI-CARB 
2100TR scintillation counter (Packard BioScience 
Company, USA).
The molecular weight data were obtained at 
35°C by using the Waters 2414 GPC system and 
Waters refractive index detector with the PLgel 
Mixed C column (polymer Laboratories, Ltd.,UK). 
Chloroform was used as an eluent at a flow rate 
of 0.8 ml/min, and a sample concentration of 1.0 
mg/ml was used. Polystyrene standards were 
used to construct a calibration curve. 
For determination of the crystallinity 
degree, Сх, scan-step spectra were read off, with 
sensitivity 0.04°, and a 2-second optical exposure 
for determination of intensity at a certain point 
(the device functioning mode was 40 kW х 
40 mkА). The IR-spectra of absorption of the 
PHA film samples were registered using the IR 
Fourier spectrometer INFALUM FT-02 (Lumex, 
Russia).
2. Preparation of microspheres
The 14C-labeled microparticles were 
prepared by the solvent evaporation technique, 
using a triple emulsion. 600 mg of the 
polymer (PHB) and 200 mg of polyethylene 
glycol (PEG40, molecular mass 40 kDa) were 
dissolved in 10 ml of dichloromethane. Then, 1 
ml of a 6 % gelatin solution (40°C) was added 
and the mixture was shaken vigorously. The 
resulting water/oil (W/O) double emulsion 
was allowed to cool to room temperature and 
then it was gradually poured into 150 ml of a 
0.5 % PVA solution, which was stirred with a 
three-blade propeller (at 2000 rpm, for 20 min) 
(Heidolph, Germany), to obtain a triple (water/
oil/water, W/O/W) emulsion. The emulsion 
was continuously mixed mechanically for 24 
h, until the solvent was completely evaporated. 
Microspheres were collected by centrifuging 
(at 10000 rpm, for 5 min), rinsed 7-8 times in 
distilled water, and freeze-dried in the LS-500 
lyophilizer (Prointex, Russia). 
3. Microsphere characterization
The size of microspheres with a diameter 
bigger than 3 µm was determined using the 
Automatic Particle Counter + Analyser system 
(Casy TTC, Scharle System GmbH, Germany). 
The obtained size distribution was used to 
describe the particle size. 
For intravenous injections a fraction of 
microspheres with a diameter smaller than 3.8 
mkm was selected, using a treck filter. The size 
of particles was estimated using the Scan master 
program of the scanning multimicroscope CMM-
2000 taking into account the parameters which 
determined the image size. The structure of 
microsphere surfaces was analyzed by electron 
microscopy, as was described previously 
(Shishatskaya et al., 2008a). 
4. Animal model 
Experiments were conducted on adult female 
Wistar rats (200-240 g each) in accordance with 
the international and Russian ethical rules for 
laboratory animals care. The rats were kept 
in an animal facility and fed a standard diet in 
accordance with the directive on maintaining 
animals and experimenting on them (Genin et 
al., 2001). A sterile suspension of microspheres 
(5 mg in 0.5 ml of physiological saline, 5×104 
cpm/g) with a diameter not more than 3.8 µm was 
injected to rats through the tail vein, without any 
anesthesia. Intact animals were used as control. 
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Three hours after the injection, 24 hours 
after the injection, and then every week, three 
animals were sacrificed by using an overdose of 
a volatile anesthetic. Their internal organs were 
removed, examined macroscopically, weighed, 
dried and ground; then, radioactivity counts 
were performed. A 100 mg sample was placed 
into a plastic vial (PerkinElmer/Packard, USA) 
containing 15 ml of dioxane scintillation solution; 
1 L dioxane contained 2,5-diphenyloxazole, 10 
g; 1,3-di-2,5-phenyloxazolyl benzene, 0.25 g; 
naphthalene, 100 g. Radioactivity counts were 
performed in the TRI-CARB 2100TR scintillation 
counter (Packard BioScience Company, USA). 
Radiocarbon was measured in the heart, lungs, 
liver, kidneys, bone marrow, and blood, without 
taking into account the radioactivity of soft and 
hard tissues and excreted metabolic products. To 
study the resorption of the polymer scaffold and 
accumulation of 14C-containing PHA degradation 
products, samples of the dried tissues were 
subjected to methanolysis, and fatty acid methyl 
esters were determined using the GCD plus 
chromatograph mass spectrometer (Hewlett 
Packard, USA). To determine high-molecular-
weight (undecomposed) polymer in the organs, it 
was extracted from the tissues with chloroform 
and precipitated with hexane. Then the polymer 
was methylated and chromatographed as 
described above; the sensitivity was 10-11 g. The 
general tissue reaction to implanted microspheres 
was investigated using conventional histological 
techniques. The samples were fixed in 10 % 
formalin and embedded in paraffin; 5-10 μm 
thick microtome sections were stained with 
hematoxylin and eosin.
5. Statistics
The results were analyzed statistically using 
the standard software package of Microsoft 
Excel. Arithmetic means and standard deviations 
were found. Significant differences between 
average values in control and treatment groups 
were tested using Student’s t-test (significance 
level: p = 0.05) by standard methods: using 
two sample equal variance, with two-tailed 
distribution. We used 3 samples (animals) per in 
vivo experiment.
Results 
1. Microspheres characterization
The microspheres were of regular spherical 
shape and had a well-developed «wrinkled» 
surface; their diameters were significantly 
heterogeneous. Fig. 1 represents a typical 
appearance of microspheres with a regular 
spherical shape having no defects or inclusions. 
Microsphere size distribution varied within the 
range from 0.50±0.02 μm to 50.00±4.62 μm. The 
fraction of the microspheres with a diameter of 
3-5 μm amounted to 21.1±1.8 %. Microspheres 
of this size are considered to be the best for 
injections. The fraction of the particles 5 to 10 
μm in diameter constituted 30.4±1.1 %, and the 
fraction of the particles 10 to 20 μm – 34.4±2.3 %. 
The largest of the harvested particles were 35 μm 
in diameter, and their fraction did not exceed 
3.5 %. The average diameter of microspheres 
was 10±0,23 μm. Particles taken for intravenous 
injection were 0.5-3.8 μm. The microparticles 
used in the experiment had an average diameter 
of 2.40 ±0.21 μm.
2. Distribution of PHB microparticles  
in internal organs
All animals that had been injected with a 
microspheres suspension were healthy and ate 
well throughout the experiment. Their body mass 
and masses of their internal organs were similar to 
those of the rats in the control group. Macroscopic 
examination of the rats’ internal organs and 
histological studies of the tissue sections did not 
show any adverse changes in them throughout the 
observation period.
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The dynamics of 14C activity concentrations 
in tissues of internal organs in the course of 
the experiment is shown in Fig. 2. Three hours 
after the injection of the microparticles into 
the bloodstream of the animals, the largest 14C 
activity concentration (14680±417 cpm×g) was 
registered in heart tissues. The second largest 
concentration of the label was determined in 
kidney tissues (7520±81 cpm×g) and the third – 
in lung tissues (5280±65cpm×g). Liver and 
spleen tissues contained similar 14C activities – 
(4400±58cpm×g). The lowest radioactivity levels 
were registered in blood and bone marrow. One 
month later, 14C activity concentration in the heart 
tissues was 4.5 times lower than its initial level 
amounting to 3240±57 cpm×g. Radioactivity 
of liver tissues dropped to 15120±90 cpm/g. 
In the tissues of kidneys and lungs decreased 
radioactivity levels were detected: from the initially 
detected, 4720±69 cpm/g and 940±97 cpm/g, 
correspondingly, to kidneys and lungs. At the 
same time, 14C concentration in the spleen tissues 
somewhat rose, which may be accounted for by 
the accumulation of polymer resorption products 
in this organ, where, in addition to hydrolytic 
enzymes, there are active macrophage-type cells, 
which resorb cell elements. Macrophages are 
known to actively degrade polyhydroxybutyrate 
(Shishatskaya et al., 2008a). 
The level of radioactivity in blood and bone 
marrow did not exceed 300 cpm/g.
Thus, the tissues of internal organs sorbed 
different amounts of intravenously injected 
microparticles. This is even more obvious 
from the analysis of the data in (Fig. 3), which 
shows in vivo accumulation of the label, taking 
into account the masses of the organs. Data 
on Fig. 2 correspond to Fig. 1, and allow us to 
make the following conclusion: the main target 
for microparticles was the liver tissue; the 
average level of accumulated 14С in liver during 
the experiment was approximately 60 % of the 
injected dose. 
Fig. 1. Micrographs of the microspheres prepared from polyhydroxybutyrate
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During the period of microparticle circulation 
a reliable decrease in the organ radioactivity was 
detected, which we believe is due to the initiated 
process of polymer matrix biodegradation and 
excretion of the label part with carbon-containing 
PHB biodegradation products. Thus, three 
hours after the injection of microparticles to the 
animals, the total radioactivity of the organs was 
38720 ± 2575 cpm/g, i.e. 80 % of the radioactivity 
of the injected dose (Fig. 4). 120 days after the 
intravenous injection the total radioactivity 
dropped to 28210 ± 2054 cpm/g, which can be 
attributed to polymer biodegradation. 
3. PHB biodegradation in internal organs
We should note here that the registered 
amounts of radiocarbon in the rats’ organs do not 
show the true accumulation of microparticles in 
the organs: PHAs are biodegradable polyesters 
and are bioresorbed in vivo by the enzymes 
Fig. 2. Dynamics of radiocarbon concentration in tissues of internal organs of the animals intravenously injected 
with 14C-labeled polymer microparticles
Fig. 3. Dynamics of radiocarbon accumulation in internal organs of the animals intravenously injected with 
14C-labeled polymer microparticles
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and cell elements of blood and tissues, and the 
polymer degradation products are removed with 
metabolites (Jendrossek et al., 2001). The 14C 
activities registered in the tissues comprise the 
radiocarbon of the high-molecular-weight polymer 
scaffold, i.e. undecomposed microparticles 
and the radiocarbon of polymer degradation 
products. 
To compare the biodegradation rates of the 
polymer in different organs and to determine 
the «lifetime» of polymer microparticles, tissues 
were subjected to chromatographic analysis. 
During the experiment, the amounts of the 
polymer substance varied in every organ. At 8 
weeks, polymer content in the heart and lungs 
dropped almost by a factor of ten compared to 
week 1. However, in our opinion, this cannot 
be accounted for by the degradation of polymer 
scaffold in these organs, but rather by the 
bloodstream washing out the initially introduced 
microparticles from the pulmonary circulation. 
Eight weeks later, polymer content in the liver 
and kidneys decreased insignificantly: 1.5 times 
in the kidneys and 1.2 times in the liver. A more 
significant, 2.5-fold, decrease was registered 
in the spleen. 12 weeks later, at the end of the 
experiment, polymer content decreased as 
compared to the values measured after an 8 week 
interval: almost twofold in the heart and lungs, 
threefold in the kidneys, 18-fold in the spleen, 
and 25-fold in the liver (Table 1).
Our results are indicative of different PHA 
biodegradation rates in animal tissues. They 
also show that at the end of the experiment the 
organs still contained high-molecular-weight 
polymer and, thus, some of the microparticles 
could have remained undecomposed. However, 
spectrometric methods used to detect high-
molecular-weight PHAs are based on registering 
fatty acid methyl esters (i.e. polymer-forming 
monomers) – products of preliminary hydrolysis 
of the polymer to monomers and their subsequent 
methylation. Thus, the presented values can 
comprise both monomers of hydroxybutyric 
acid resulting from methanolysis of the high-
molecular-weight polymer and monomer products 
of its natural biological degradation caused by 
enzymes and cells of the organs. 
The high-molecular-weight (undecomposed) 
polymer was extracted from the samples and 
analyzed. That was done to determine the 
concentration of the high-molecular-weight 
undecomposed polymer in internal organs 
at different time points after the injection of 
microparticles (Table 2). One week after the 
injection, the polymer content registered in 
Fig. 4. Dynamics of total 14C radioactivity in animal organism
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the lungs, heart, and liver was larger than that 
registered in the spleen and kidneys. Eight weeks 
after the injection, the polymer content in the 
lungs and heart dropped dramatically (similarly 
to the data of Table 1), but that was rather due to 
particle washout than degradation processes. This 
conclusion was confirmed by the measurements 
of tissue radioactivity. It should be noted that the 
data at the end of a 12 week interval given in tables 
1 and 2 differ significantly: chromatography of 
the tissues determined much higher amounts of 
the polymer substance (Table 1) than the amounts 
of the high-molecular-weight polymer recovered 
from the organs (Table 2). This leads to the 
conclusion that at the end of the experiment, the 
major portion of the 14C-labeled polymer was 
present in vivo as monomers of hydroxybutyric 
acid and its low-molecular-weight degradation 
products. 
The second important conclusion based 
on the data of Table 2 is that some polymer 
microparticles remained undecomposed in the 
animals’ organs at different time points of the 
experiment. Finally, the fact that the examined 
organs, especially the liver and the spleen, 
contained relatively low amounts of the polymer, 
while radioactivity of the tissues was high, is 
indicative of the rapid degradation of the polymer 
scaffold in them.
Discussion
In this paper, we have presented the results of 
investigation into the distribution of intravenously 
injected 14C-labeled polymer (PHB) microparticles 
in internal organs of laboratory animals and the 
localization of PHA biodegradation products.
There is substantial literature data on the 
in vitro and in vivo kinetics of drug release 
from polymer matrices, their medicinal 
effectiveness, and the possibilities of targeted 
delivery (Arulsudar et al., 2003; Petri et al., 2007; 
Bazzo et al., 2008). However, there are rather 
few studies that describe investigations of the 
in vivo distribution and dynamics of infused 
microparticles, especially PHA-based ones, 
although this aspect is obviously very important.
Table 1. Results of chromatographic analysis of methyl esters of hydroxybutyrate monomers contained in tissues 
of rats’ internal organs 
Organ
PHB content (1 × 10-4 mg/organ)
1 week 8 weeks 12 weeks
heart 1527 132 75
lungs 1694 111 56
liver 5861 4889 197
spleen 606 251 14
kidneys 189 124 43
Table 2. Residual high-molecular-weight polymer in tissues of rats’ internal organs
Оrgan
PHB content (1 × 10-4 mg/organ)
1 week 8 weeks 12 weeks
heart 420 30 5
lungs 600 5 6
liver 360 110 80
spleen 6 10 5
kidneys 16 20 7
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Distribution of microparticles and the rates 
of their elimination from the body depend on 
many factors, and the available literature data on 
mechanisms of biodistribution are contradictory. 
Most authors report that the main targets of 
intravenously injected particles are the organs of 
the reticuloendothelial system, namely the liver 
and the spleen (Owens et al., 2006). In one of the 
first published studies devoted to this subject it 
was reported that the distribution of 141C-labeled 
polystyrene/divinylbenzene microparticles 
intravenously injected to dogs depended on 
the size of the particles and that particles of a 
larger diameter were taken up by the organs at 
a higher rate (Kanke et al., 1980). Microspheres 
of 7 µm and 12 µm in diameter were mostly 
retained in the lungs, and 3-5 µm ones – in the 
liver and spleen. Four weeks after the injection of 
microspheres, no phagocytosis of microparticles 
by lung macrophages was observed. Drug-loaded 
bovine serum albumin based microparticles with 
an average diameter of 2.58 µm were injected 
intravenously, into the tail vein of mice. The 
average distribution efficiency of the particles 
was found to be 11.74 % in the liver, 8.50 % in 
the kidneys, 7.69 % in the lungs, and 5.67 % in 
the spleen after 24 h (Dandagi et al., 2006). In 
another work, the authors studied the distribution 
of polylactide-based microparticles labeled 
[99mTc(CO)3]+ after the intravenous injection to 
mice during the period of six hours after the 
beginning of the experiment. It was found that 
the main target for the PLG microparticles with 
a diameter of 0.2-3 µm was the liver (55 % of 
the injected dose), the second largest, in terms 
of label inclusion, were the tissues of lungs and 
spleen (Saatchi et al., 2009).
Ballot and her co-authors studied the 
kinetic biodistribution of nanoparticles labeled 
with rhenium and technetium in rats. The 
particles were composed of a liquid lipidic 
core (triglycerides) surrounded by a surfactant 
shell (2-hydroxystearate of polyethylene glycol 
and lecithin); the mean size of the particles 
was 45 nm to 49 nm. Dynamic scintigraphic 
acquisitions revealed relatively long activity 
circulation in blood before location mainly 
in the liver and spleen. High activity in the 
cardiac area and low hepatic retention were 
observed within one hour after the injection. 30 
minutes after the beginning of the experiment, 
nanoparticles were predominantly taken up 
by the liver and spleen. 24 hours after the 
injection the remaining activities in the liver 
and spleen were 5 % and 2.5 % of the initial 
value, respectively (Ballot et al., 2006). 
Different results were obtained in experiments 
with water-soluble poly(2-methyl-2-oxazoline) 
administered to mice by tail vein injection. The 
intravenously injected water-soluble polymer 
was not retained in the tissues but was quickly 
excreted by renal glomerular filtration. The 
lowest concentration of the polymer was found 
in the brain, indicating that poly(2-methyl-
2-oxazoline) does not cross the blood-brain 
barrier. A slight increase of radioactivity was 
registered in the liver, spleen, and bone marrow 
within 24 hours (Graether et al., 2007). 
One of the approaches to prolonging the 
time of nanoparticle circulation in the body 
is regulation of particle sizes and creation of 
hydrophilic surface on the nanomatrices. Shenoy 
and co-authors determined the distribution 
and localization of nanoparticles based on 
poly(ethylene oxide)-modified poly(β-amino 
ester) and poly(ethylene oxide)-modified 
poly(caprolactone). 11In was chosen as the label 
for the nanoparticles mainly due to its short half-
life and its availability in the lipophilic form 
for encapsulation in nanoparticles. Both types 
of nanoparticles showed higher tendency for 
accumulation in the liver, spleen and lungs during 
the initial phase and in the kidney at the later 
stages of biodistribution (Shenoy et al., 2005). 
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Poly(ethylene oxide)-modified nanoparticles had 
higher circulation times than particles without 
a PEO coating. Glen S. Kwon and co-authors 
studied biodistribution of 30 nm to 50 nm 
polymeric micelles based on block copolymers 
of polyethylene oxide and poly(aspartic) acid 
with covalently bound Adriamycin, which were 
labeled by 14C-benzylamine. The micelles were 
studied as potential drug carriers. The authors 
registered prolonged circulation of micelles in 
blood (concentration of the radiolabel in blood 
gradually decreased from 50 % to 10 % of the 
injected dose within 24 h and then micelles 
accumulated in the liver and spleen) (Know et al., 
1993). 
Rather few in vivo investigations of 
the distribution of microparticles based on 
polyhydroxybutyrate or any other PHA have 
been reported in the available literature. 
Bissery and co-authors studied distribution of 
microspheres based on 14C-labeled PHB, and 
1-12 µm microspheres intravenously injected to 
mice were mostly found in the lungs (Bissery 
et al., 1984). Another distribution pattern was 
observed for smaller (0.3-0.5 µm) PHB particles 
injected to rats via the tail vein – at 2.5 h 86 % of 
radioactivity was registered in the liver, and the 
lungs and the spleen contained 2.5 % each (Saito 
et al., 1991).
Those results differed from Bissery’s and 
Kanke’s data. Saito et al. presumed that this could 
be accounted for by the difference in diameter of 
the particles and animal species used. We should 
note, however, that Saito et al. investigated native 
PHB granules recovered from Zoogloea ramigera 
cells grown on 14C-labeled glucose rather than 
polymer-based microparticles. Hence, in addition 
to being very small, PHB granules also differed 
from Bissery’s microparticles in their structure 
and chemical composition.
The pattern of the distribution of PHB 
particles under 3.8 µm in diameter in internal 
organs of laboratory animals that we obtained in 
our experiment is generally comparable with the 
data reported by other authors that used different 
polymers (Bissery et al., 1984; Ballot et al., 2006). 
The comparison of degradation of microparticle 
polymer scaffold in different organs showed that 
PHB is resorbed at the highest rate in the spleen 
and liver. In addition, at 12 weeks we observed 
undecomposed microparticles, which led us to 
the conclusion that PHB particles can be used as 
sustained drug delivery systems. 
In conclusion, this study shows that 
polyhydroxybutyrate microparticles are suitable 
for intravenous administration; tissues of internal 
organs accumulate different concentrations of 
polymer microparticles, and polymer scaffold is 
degraded in them at different rates. The presence 
of high-molecular-weight polymer scaffold 
registered in internal organs, which is indicative 
of microparticles remaining undecomposed, 
suggests that polyhydroxybutyrate can be used to 
construct systems for sustained (up to 12 weeks) 
drug delivery to tissues of internal organs via 
intravenous administration. 
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Распределение и резорбция полимерных микрочастиц  
в тканях внутренних органов лабораторных животных  
при внутривенном введении
Е.И. Шишацкаяа,б, А.В. Гореваа, 
Г.С. Калачеваа, Т.Г. Воловаа,б
а Институт биофизики СО РАН, 
Россия 660036, Красноярск, Академгородок
б Сибирский федеральный университет, 
Институт фундаментальной биологии и биотехнологии, 
Россия 660041, Красноярск, пр. Свободный, 79
С применением резорбируемого полимера гидроксимасляной кислоты, меченого по 14С, 
получены микрочастицы (диаметром менее 3,8 мкм), которые были введены лабораторным 
животным (крысы линии Вистар) в хвостовую вену без негативных последствий для роста и 
развития животных и без изменения макро- и микроскопической структуры тканей органов. 
Изучено распределение микрочастиц среди внутренних органов и динамика накопления 
углеродсодержащих продуктов разрушения полимера во внутренних органах. Показано, что 
основной мишенью для частиц являются ткани печени, а также почек и селезенки. Наиболее 
активное разрушение полимерного матрикса микрочастиц происходит в селезенке и печени. 
Выявленное наличие высокомолекулярного полимерного матрикса в органах, свидетельствует 
о целостности микрочастиц и возможности долговременного (до 12 недель) функционирования 
препарата в виде полимерных микрочастиц in vivo.
Ключевые слова: резорбируемый полигидроксибутират, микрочастицы, внутривенное 
введение, 14С, ткани внутренних органов.
